Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Pharmaceutics|June 27, 2022
Manufacture of tablets with structurally-controlled drug release using rapid tooling injection mouldingErin Walsh, Natalie Maclean, Alice Turner, et al.
European Journal of Medicinal Chemistry|September 13, 2019
Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2)Buthaina Hussein, Balqis Ikhmais, Manikandan Kadirvel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancyBeatrice M Seddon, Geoffrey S Payne, Laura Simmons, et al.
Mabs|May 28, 2025
Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stabilityPaul Considine, Panida Punnabhum, Callum G Davidson, et al.
International Journal of Pharmaceutics|August 20, 2022
Linked experimental and modelling approaches for tablet property predictionsHikaru G Jolliffe, Ebenezer Ojo, Carlota Mendez, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|February 17, 2020
An interlaboratory investigation of intrinsic dissolution rate determination using surface dissolutionKelly Etherson, Claire Dunn, Wayne Matthews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumorsMalcolm Ranson, Mark R Middleton, John Bridgewater, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 13, 2013
Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needsChristel A S Bergström, René Holm, Søren Astrup Jørgensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2020
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid TumorsRobert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumoursLaura Horsley, Jeff Cummings, Mark Middleton, et al.
Pageof 3